
|Podcasts|July 26, 2021
Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
Author(s)Elizabeth Yeu, MD, Alex Delaney-Gesing
Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical terminates proposed acquisition by Alcon
2
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
International meta-analysis highlights elevated ocular risk in Clade I Monkeypox
5












































